Another independent biotech is acquired as Merck buys Cubist for $9.5B

Merck & Co. pending's acquisition of Cubist Pharmaceuticals for $9.5 billion is a win for the Lexington company and for the antibiotics field as a whole...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.